Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H11NO3 |
| Molecular Weight | 193.1992 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)NC1=CC=C(CC(O)=O)C=C1
InChI
InChIKey=MROJXXOCABQVEF-UHFFFAOYSA-N
InChI=1S/C10H11NO3/c1-7(12)11-9-4-2-8(3-5-9)6-10(13)14/h2-5H,6H2,1H3,(H,11,12)(H,13,14)
| Molecular Formula | C10H11NO3 |
| Molecular Weight | 193.1992 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
http://www.clinexprheumatol.org/article.asp?a=1640
Curator's Comment: description was created based on several sources, including
http://www.clinexprheumatol.org/article.asp?a=1640
Actarit (MS-932) is an anti-inflammatory drug developed in Japan for use in rheumatoid arthritis (RA). Actarit suppresses adjuvant arthritis through modulation of the immune system. Actarit acts on RA synovial cells to reduce cell-cell interactions with autologous synovium infiltrating lymphocytes and to inhibit proinflammatory cytokine and MMP production, leading to amelioration of symptoms of RA.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Effect of actarit combination therapy in patients with active rheumatoid arthritis resistant to gold agents]. | 2001 Jun |
|
| The effect of methotrexate on bone metabolism markers in patients with rheumatoid arthritis. | 2006 |
|
| A new low-field extremity magnetic resonance imaging and proposed compact MRI score: evaluation of anti-tumor necrosis factor biologics on rheumatoid arthritis. | 2009 |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Actarit was administered at 300 mg/day and was used throughout the study period. The duration of treatment was 24 weeks. During this study there were no significant adverse reactions requiring the withdrawal of treatment.
300 mg/day, duration of treatment is 24 weeks.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:41:06 GMT 2023
by
admin
on
Fri Dec 15 15:41:06 GMT 2023
|
| Record UNII |
HW5B6351RZ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29634
Created by
admin on Fri Dec 15 15:41:06 GMT 2023 , Edited by admin on Fri Dec 15 15:41:06 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
170317
Created by
admin on Fri Dec 15 15:41:06 GMT 2023 , Edited by admin on Fri Dec 15 15:41:06 GMT 2023
|
PRIMARY | |||
|
2018
Created by
admin on Fri Dec 15 15:41:06 GMT 2023 , Edited by admin on Fri Dec 15 15:41:06 GMT 2023
|
PRIMARY | |||
|
DTXSID0020020
Created by
admin on Fri Dec 15 15:41:06 GMT 2023 , Edited by admin on Fri Dec 15 15:41:06 GMT 2023
|
PRIMARY | |||
|
242-511-3
Created by
admin on Fri Dec 15 15:41:06 GMT 2023 , Edited by admin on Fri Dec 15 15:41:06 GMT 2023
|
PRIMARY | |||
|
HW5B6351RZ
Created by
admin on Fri Dec 15 15:41:06 GMT 2023 , Edited by admin on Fri Dec 15 15:41:06 GMT 2023
|
PRIMARY | |||
|
CHEMBL1885632
Created by
admin on Fri Dec 15 15:41:06 GMT 2023 , Edited by admin on Fri Dec 15 15:41:06 GMT 2023
|
PRIMARY | |||
|
m1394
Created by
admin on Fri Dec 15 15:41:06 GMT 2023 , Edited by admin on Fri Dec 15 15:41:06 GMT 2023
|
PRIMARY | Merck Index | ||
|
ACTARIT
Created by
admin on Fri Dec 15 15:41:06 GMT 2023 , Edited by admin on Fri Dec 15 15:41:06 GMT 2023
|
PRIMARY | |||
|
SUB05255MIG
Created by
admin on Fri Dec 15 15:41:06 GMT 2023 , Edited by admin on Fri Dec 15 15:41:06 GMT 2023
|
PRIMARY | |||
|
18699-02-0
Created by
admin on Fri Dec 15 15:41:06 GMT 2023 , Edited by admin on Fri Dec 15 15:41:06 GMT 2023
|
PRIMARY | |||
|
6549
Created by
admin on Fri Dec 15 15:41:06 GMT 2023 , Edited by admin on Fri Dec 15 15:41:06 GMT 2023
|
PRIMARY | |||
|
100000087677
Created by
admin on Fri Dec 15 15:41:06 GMT 2023 , Edited by admin on Fri Dec 15 15:41:06 GMT 2023
|
PRIMARY | |||
|
84
Created by
admin on Fri Dec 15 15:41:06 GMT 2023 , Edited by admin on Fri Dec 15 15:41:06 GMT 2023
|
PRIMARY | |||
|
C73298
Created by
admin on Fri Dec 15 15:41:06 GMT 2023 , Edited by admin on Fri Dec 15 15:41:06 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE |
URINE
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
